Teva Pharmaceutical Industries

Latest news

• Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome (opens in a new tab)

  Yahoo Finance UK · Oct 2, 2026

• TD Cowen Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) (opens in a new tab)

  MarketBeat · Oct 1, 2026

• Branded Medicines and Pipeline Successes Drive Teva Pharmaceutical Industries’ (TEVA) Margin Expansion (opens in a new tab)

  Yahoo Finance · Oct 1, 2026

• TD Cowen Initiates Teva Pharmaceutical Industries at Buy With $55 Price Target (opens in a new tab)

  Yahoo Finance · Oct 1, 2026

• Teva Pharmaceutical and Samsung Bioepis Forge Global Biosimilar Partnership (TEVA) (opens in a new tab)

  GuruFocus · Oct 1, 2026

• Samsung Bioepis, Teva expand biosimilar pact to target US and Europe - CHOSUNBIZ (opens in a new tab)

  Chosunbiz · Oct 1, 2026

• Samsung Bioepis, Teva enter commercialization agreement on 6 biosimilar candidates (opens in a new tab)

  The Korea Times · Oct 1, 2026

• Teva names Serge Rogasik as CEO of API, CDMO business (opens in a new tab)

  TradingView · Sep 30, 2026

• Samsung Bioepis and Teva Expand Strategic Partn… | UNI India (opens in a new tab)

  uniindia.com · Sep 30, 2026

• Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Moderate Buy" from Analysts (opens in a new tab)

  MarketBeat · Sep 30, 2026

• Teva's Branded Drugs Take Center Stage in Its Growth Strategy (opens in a new tab)

  TradingView · Sep 29, 2026

• Teva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround (opens in a new tab)

  fool.com · Sep 29, 2026

• Teva Pharmaceutical Industries (NYSE:TEVA) Stock Forecast & Analyst Predictions (opens in a new tab)

  Simply Wall Street · Sep 29, 2026

• Teva Pharmaceutical Industries Gains FDA Nod for Degevma Biosimi (opens in a new tab)

  GuruFocus · Sep 28, 2026

• Form 4 TEVA PHARMACEUTICAL INDUSTRIES LTD For: 27 September By Investing.com (opens in a new tab)

  Investing.com Canada · Sep 27, 2026

• Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET (opens in a new tab)

  riauone.com · Sep 24, 2026

• Teva Pharmaceutical Industries stock trades 4.36 percent below its yearly high (opens in a new tab)

  AD HOC NEWS · Sep 24, 2026

• Teva releases Q3 2026 Aide Memoire ahead of November earnings (opens in a new tab)

  scanx.trade · Sep 23, 2026

• Teva Pharmaceutical Industries Ltd. to Report Third Quarter 2026 Financial Results on November 3, 2026 (opens in a new tab)

  Quiver Quantitative · Sep 23, 2026

• Third-quarter results are set for 7 a.m.; Teva's call follows at 8. (opens in a new tab)

  Stock Titan · Sep 23, 2026

• Teva Releases Q3 2026 Aide Memoire (opens in a new tab)

  GlobeNewswire · Sep 23, 2026

• Oppenheimer Initiates Coverage on Teva Pharmaceutical Industries (NYSE:TEVA) (opens in a new tab)

  MarketBeat · Sep 23, 2026

• Teva Eyes New Growth Phase After Securing Investment-Grade Ratings (opens in a new tab)

  TradingView · Sep 23, 2026

• Brian Savage Sells 7,342 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock (opens in a new tab)

  MarketBeat · Sep 22, 2026

• Teva Pharmaceutical Industries (NYSE:TEVA) Director Roberto Mignone Sells 367,600 Shares (opens in a new tab)

  MarketBeat · Sep 22, 2026

• Director’s fund exits Teva Pharmaceutical Industries (TEVA) stake in one-day sale (opens in a new tab)

  Stock Titan · Sep 22, 2026

• Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline (opens in a new tab)

  Yahoo Finance · Sep 22, 2026

• Teva Pharmaceutical Industries (TEVA), Why Is It Back In The Spotlight? (opens in a new tab)

  Yahoo Finance · Sep 21, 2026

• Teva (NYSE: TEVA) legal chief files $273K share-sale notice (opens in a new tab)

  Stock Titan · Sep 21, 2026

• Teva Pharmaceutical Industries stock gains as NYSE direct listing and new schizophrenia data underli (opens in a new tab)

  AD HOC NEWS · Sep 19, 2026